A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hormone-Refractory Prostate Cancer
Interventions
DRUG

Docetaxel, Carboplatin

"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT00675545 - A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients | Biotech Hunter | Biotech Hunter